Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Pindolol

Plain-language summaryIntrigue 48 / 100

Pindolol is an old beta-blocker, FDA-approved in 1982, that lowers blood pressure by quieting the heart. What makes it interesting outside cardiology is a side activity: it binds tightly to a serotonin receptor (5-HT1A) that normally throttles serotonin release. By turning off that throttle alongside an SSRI antidepressant, pindolol was hypothesized to make the SSRI kick in faster (days rather than weeks). Trials produced mixed results, with some studies showing accelerated response in depression and others showing nothing. It is still used occasionally in psychiatry as an SSRI booster, but never became standard practice. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

37/100

Old beta-blocker with real 5-HT1A probe value, but inconsistent clinical signal limits excitement

Look, pindolol is one of those compounds where the mechanism is more interesting than the compound itself. Approved for hypertension in 1982, it spent years as a fairly unremarkable non-selective beta-blocker until researchers noticed something: it binds 5-HT1A receptors with real affinity (Ki around 50 nM) and acts as a partial agonist there. That property got it drafted into psychiatric research as an SSRI augmentor in the 1990s, and for a while it was genuinely intriguing.

The hypothesis was elegant. SSRIs lose their first two weeks to autoreceptor-mediated negative feedback at the raphe. Add a 5-HT1A partial agonist like pindolol, and you desensitize those presynaptic autoreceptors faster, in theory compressing the latency to antidepressant effect. Multiple placebo-controlled trials tested this through the late 1990s and into the 2000s. Some showed a real 1-2 week acceleration. Others did not. The meta-analyses are frustrating reading: positive signal on onset, weaker or null signal on overall efficacy. That inconsistency is the core problem with this compound as a research target, and we think it explains why the field mostly moved on.

Where pindolol still earns its place in a serious library is as a probe. Its specific combination of beta-blockade plus 5-HT1A partial agonism is hard to replicate with other tools. If you’re running mechanistic work on presynaptic serotonin autoreceptor desensitization, or trying to parse the cardiovascular from the serotonergic components of a drug interaction, pindolol gives you a handle thats difficult to replace. Its been called the canonical 5-HT1A binding beta-blocker in mechanism studies for good reason. Buspirone is more selective at 5-HT1A but lacks the beta component entirely. That combination makes pindolol genuinely useful for dissecting receptor contributions in mixed-pharmacology contexts.

What we dont love: the SSRI augmentation question is basically settled as disappointing, the compound is old enough that most interesting questions about it have been asked, and the short half-life (3-4 hours) is a practical nuisance in research designs. Its not a novel mechanism, not a novel compound, and the translational arrow from preclinical to clinical is pointing in different directions depending on which trial you read.

Honestly, if youre building a research program around serotonin autoreceptor biology and need a pharmacological tool with a specific dual profile, pindolol is worth having. As a primary research target in its own right? The case is thin. The probe utility is real but narrow, and the clinical inconsistency means the translational story never really closed.

Novelty

20

Mechanism promise

42

In-category differentiation

35

Evidence quality

45

Translational signal

35

Research bench value

52

Rationale Pindolol scores as a niche probe because its 5-HT1A autoreceptor work is genuinely useful for serotonin pharmacology, but the compound is a 1982 FDA approval with mixed augmentation trial data; bench utility saves it from obscurity, novelty and translational inconsistency drag the overall down.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Non-selective beta-adrenergic antagonist with 5-HT1A partial agonism

A non-selective beta-blocker with intrinsic 5-HT1A partial agonism; investigated as an SSRI augmenting agent.

Abstract

Pindolol (1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; CAS 13523-86-9; molecular formula C14H20N2O2; molecular weight 248.32) is a non-selective beta-adrenergic antagonist with intrinsic sympathomimetic activity (partial agonism) and 5-HT1A partial agonism, approved by the FDA in 1982. The compound’s distinguishing pharmacological feature in psychiatric research is high-affinity 5-HT1A binding (Ki approximately 50 nM) with partial agonist activity at presynaptic autoreceptors; concurrent administration with an SSRI desensitizes the autoreceptor more rapidly than the SSRI alone, hypothetically accelerating the antidepressant response. Multiple placebo-controlled trials in the 1990s and 2000s reported faster onset (1 to 2 weeks shorter latency) but inconsistent overall efficacy improvement. Plasma half-life is 3 to 4 hours; metabolism is hepatic. Approved indications in cardiology include hypertension and angina; the SSRI augmentation use remains off-label. Used as the canonical 5-HT1A binding beta-blocker in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-257Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Toremifene

Plain-language summaryIntrigue 45 / 100

Toremifene (Fareston) is a chlorinated cousin of tamoxifen, approved in 1997 for postmenopausal metastatic breast cancer. It shares the same triphenylethylene scaffold and tissue-selective estrogen-receptor profile, with two practical differences: it is metabolized less by CYP3A4 (so fewer drug interactions) and produces a different metabolite mix (notably no endoxifen). Clinical efficacy in breast cancer is broadly similar to tamoxifen. It is used as an alternative when tamoxifen is poorly tolerated or when its drug interactions cause problems. Less common in the US than internationally. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

Tamoxifen’s chlorinated backup option with no real research edge and a weaker metabolite story

Look, toremifene is basically tamoxifen with a chlorine atom. That’s not meant to be dismissive—the Orion Pharma team had real reasons to develop it, and the FDA agreed it deserved approval in 1997—but from a research-merit standpoint, it’s hard to build a compelling case for this compound over its parent scaffold.

The mechanism is textbook SERM: tissue-selective ER modulation, antagonist in breast tissue, partial agonist in bone and endometrium. Nothing new here. Tamoxifen pioneered this approach in the 1970s and toremifene arrived two decades later offering mostly pharmacokinetic refinements. The key pharmacological difference is the metabolite profile: tamoxifen generates endoxifen via CYP2D6, and endoxifen is substantially more potent than either parent compound. Toremifene doesn’t produce an equivalent high-potency active metabolite. For researchers studying SERM pharmacology, that’s not a selling point—it’s actually a gap in the mechanistic story.

What toremifene does offer is a slightly cleaner CYP3A4 interaction profile and different DDI considerations. That matters clinically when managing polypharmacy in oncology patients. As a bench tool, its less clear why you’d reach for toremifene over tamoxifen when the latter has four decades of reference literature and a better-characterized metabolite cascade. The translational evidence is real—multiple phase 3 trials supported the approval—but the signal is essentially non-inferior to tamoxifen in ER-positive postmenopausal breast cancer rather than superior on any measurable axis.

Off-label PCT use is documented in the performance-enhancement community, mostly as a tamoxifen substitute when availability is constrained. Researchers in endocrine physiology occasionally use it in protocols studying ER-mediated gonadotropin feedback, but tamoxifen has more reference data and endoxifen profiling adds mechanistic depth that toremifene cant match. The half-life difference (roughly 5 days vs. 5-7 days for tamoxifen) is a minor practical variable, not a research hook.

We don’t think there’s a compelling angle here that tamoxifen doesn’t cover better. Evidence quality scores reasonably given FDA approval and real trial replication, but novelty is near floor, differentiation is arguably negative (the absent endoxifen analog is a genuine limitation for mechanism studies), and bench value is low because this compound isn’t the reference tool for anything. Honestly, the most interesting research question surrounding toremifene is probably why the absence of endoxifen generation doesn’t translate to worse clinical outcomes—which says more about endoxifen biology than about toremifene’s merit. Fine clinical backup. As a research target or probe, we’d deprioritize it.

Novelty

18

Mechanism promise

22

In-category differentiation

18

Evidence quality

63

Translational signal

65

Research bench value

22

Rationale Toremifene is a 1997 FDA-approved tamoxifen analog whose primary pharmacological distinction is the absence of an endoxifen equivalent, which is a liability not an asset. Evidence quality earns credit from real phase 3 trials, but novelty and differentiation are near floor given the compound is mechanistically redundant with a better-characterized parent scaffold.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Triphenylethylene SERM (tamoxifen analog)

A chlorinated triphenylethylene SERM analog of tamoxifen; alternative SERM in postmenopausal breast cancer.

Abstract

Toremifene (2-[4-[(Z)-4-chloro-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethylethanamine; CAS 89778-26-7; molecular formula C26H28ClNO; molecular weight 405.96) is a triphenylethylene SERM developed at Orion Pharma (Finland) and approved by the FDA in 1997 under the trade name Fareston. The compound is a chlorinated analog of tamoxifen, sharing the triphenylethylene scaffold and tissue-selective ER modulation profile. Pharmacokinetic differences from tamoxifen include reduced CYP3A4-dependent metabolism (decreasing some drug-drug interaction potential) and a different metabolite spectrum (notably absent the highly active endoxifen analog of tamoxifen). Approved for metastatic breast cancer in postmenopausal women with ER-positive or ER-unknown tumors. Off-label PCT use in athletes is documented. Plasma half-life is approximately 5 days. Adverse events parallel tamoxifen including thromboembolism and hot flashes. Used as a tamoxifen alternative in clinical and research contexts.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-273Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Levothyroxine (T4)

Our opinion on this compoundEstablished workhorse

41/100

The canonical hypothyroidism workhorse, mature beyond argument, with near-zero research novelty

Look, levothyroxine is the most prescribed drug in the United States. That sentence alone should tell you everything you need to know about where it sits on the research-interest spectrum. When something is this thoroughly characterized, this embedded in standard-of-care medicine, the frontier questions arent really about the compound anymore.

The mechanism is completely understood. T4 is a prohormone. Deiodinases D1 and D2 convert it to active T3 in target tissues. T3 binds thyroid hormone receptors TR-alpha and TR-beta, which are nuclear receptors driving gene transcription programs governing metabolism, thermogenesis, cardiac function, neurological development, and protein synthesis. We’ve known all of this for a long time. There’s no elegant new biology here, no dual-target surprise, no mechanism that reframes a whole field. Its a single-pathway prohormone doing exactly what a prohormone does.

What we do credit it for: as a reference compound for T4-biology work, its the canonical standard. Deiodinase enzyme assays, tissue-specific T4-to-T3 conversion studies, thyroid hormone receptor binding experiments — if you’re running that kind of work, levothyroxine is your T4. That earns it a real bench value score, not a heroic one. You wouldnt study deiodinase biology without it, but you wouldnt build a research program around it either.

The evidence quality and translational signal scores are genuinely high because the clinical record is enormous. Multiple decades of randomized data, regulatory approval in 1955, replicated across every conceivable patient population. The Synthroid vs. generic bioequivalence debates of the late 1990s and the absorption interaction literature are among the more practically useful pieces of pharmacokinetic research in all of thyroid medicine. None of that is exciting from a frontier standpoint; all of it is useful if youre doing clinical or PK work in the thyroid space.

Honestly, the interesting research questions adjacent to T4 right now are elsewhere: the debate over T4-only vs. T4/T3 combination therapy and what it means for deiodinase polymorphisms; the tissue-specific hypothesis about local D2 activity in brain vs. periphery; the emerging pharmacogenomics around DIO2 variants. Those questions involve T4, but theyre not really questions about T4. Levothyroxine the compound is the solved variable; the biology around its conversion and receptor selectivity is where any remaining signal lives. We score it where the rubric forces it: high evidence, low novelty, net 41.

Novelty

8

Mechanism promise

16

In-category differentiation

20

Evidence quality

90

Translational signal

88

Research bench value

50

Rationale Levothyroxine scores extremely high on evidence and translational signal because it is, simply, one of the most validated drugs in human medicine — but novelty, mechanism interest, and differentiation are all basement-tier for the same reason: theres nothing left to discover about T4 replacement that hasn’t been settled for decades. The overall of 41 reflects this tension: outstanding clinical data dragging up a compound that offers essentially nothing to a research frontier investigator.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Thyroid prohormone (T4)

Synthetic thyroxine; the standard hypothyroidism treatment and the most prescribed drug in the United States.

Abstract

Levothyroxine (3,3′,5,5′-tetraiodo-L-thyronine, T4; CAS 51-48-9; molecular formula C15H11I4NO4; molecular weight 776.87) is synthetic L-thyroxine, the principal thyroid hormone produced by the thyroid gland. Approved by the FDA from 1955 (multiple manufacturers; brands include Synthroid, Levoxyl, Tirosint). The compound is a prohormone: T4 is converted by deiodinases (D1, D2) to active T3 in target tissues. The prohormone strategy provides smoother plasma levels than direct T3 administration, reflecting the long T4 half-life (approximately 7 days). Approved indications include primary, secondary, and tertiary hypothyroidism; thyroid cancer suppression therapy; goiter; and myxedema coma. Levothyroxine is the most prescribed drug in the United States by prescription count. Plasma half-life is approximately 7 days; absorption is impaired by food, calcium, iron, and proton pump inhibitors, requiring administration on an empty stomach with at least 4-hour spacing from interfering substances. Used as the canonical T4 reference compound.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-289Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Hydergine (Ergoloid Mesylates)

Our opinion on this compoundEstablished workhorse

28/100

Historical ergoloid mixture with diffuse mechanism, inconsistent modern evidence, and no competitive angle against current alternatives

Look, Hydergine has a genuinely interesting pedigree. Albert Hofmann developed it at Sandoz in the 1940s, and for several decades it was among the most-prescribed drugs on the planet for age-related cognitive decline. That history matters as context. But historical ubiquity and research merit in 2026 are very different things, and Hydergine scores low here for reasons that get clearer the closer you look.

The pharmacology is honestly a mess. It’s a fixed mixture of four dihydrogenated ergoloid alkaloids in a 3:3:2:1 ratio, and the proposed mechanisms read like a catalog of everything researchers thought might matter in 1965: alpha-adrenergic antagonism, weak dopaminergic and serotonergic modulation, some effect on neuronal energy metabolism, and antioxidant activity the abstract itself describes as weak. None of that is factually wrong. But none of it is a crisp pharmacological hypothesis either. You’re not probing a defined receptor system with a selective tool; you’re applying a multi-component ergoloid mixture to a preparation and watching a diffuse readout. The mechanism being incompletely characterized after 70-plus years of use is not a sign of deep mystery worth investigating. It’s a sign the signal was never clean enough to resolve.

The evidence picture is even harder to defend. Cochrane-style systematic reviews of Hydergine for dementia and cognitive decline have repeatedly returned inconsistent benefit, with effect sizes that are modest at best and unreliable across trials. This isnt a compound that lost a fair fight to superior competitors. It’s a compound whose initial approvals predated rigorous RCT design, and when methodology improved, the signal did not hold up. Cholinesterase inhibitors and memantine have replaced it in clinical practice for well-documented reasons, and no serious dementia or cognitive aging program is anchored on ergoloid alkaloids today.

Differentiation is essentially negative. On every dimension that matters for a 2026 research program, Hydergine is outclassed: cleaner mechanism compounds exist for each of its proposed targets individually, and the multi-target case is weaker than it looks because the components were not rationally combined for synergy.

What we think: the only realistic bench use-case is as an ergoloid reference standard for comparative alkaloid pharmacology or for historical context in nootropic mechanism reviews. That keeps bench value from hitting the floor entirely, but it doesnt rescue the compound as an active research target. The frontier has moved well past it.

Novelty

20

Mechanism promise

28

In-category differentiation

20

Evidence quality

42

Translational signal

30

Research bench value

38

Rationale Developed in the 1940s and once globally ubiquitous, Hydergine’s multifactorial mechanism remains incompletely characterized and modern systematic reviews return inconsistent cognitive benefit; it has been supplanted clinically by cholinesterase inhibitors and retains only narrow ergoloid reference value for bench work.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Ergoloid mixture (dihydroergocornine, dihydroergocristine, dihydroergocryptine)

A mixture of dihydrogenated ergoloid alkaloids; used historically for cognitive decline and as a senescence-associated nootropic.

Abstract

Hydergine (codergocrine mesylate; CAS 8067-24-1; mixture of dihydroergocornine, dihydroergocristine, and dihydroergocryptine alpha and beta isomers in 3:3:2:1 ratio; molecular weight approximately 660 to 700 Da) is a mixture of dihydrogenated ergoloid alkaloids developed at Sandoz (now Novartis) by Albert Hofmann in the 1940s. The compound was approved for senescence and senile mental status in many countries from the 1950s onward; it was once among the most prescribed drugs globally. Mechanism is multifactorial and incompletely characterized: alpha-adrenergic antagonism, dopaminergic and serotonergic effects, modulation of neuronal energy metabolism, and weak antioxidant activity. Modern systematic reviews have produced inconsistent evidence of cognitive benefit; the compound is largely supplanted in clinical practice by cholinesterase inhibitors and memantine for dementia. Plasma half-life is approximately 5 hours. Used as a historical nootropic and ergoloid reference compound.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-307Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Anandamide (AEA)

Our opinion on this compoundNiche research probe

46/100

Canonical endocannabinoid reference probe, irreplaceable in assays but impractical as an administered compound

Anandamide occupies a strange position in the research compound library. It’s genuinely foundational. Devane and Mechoulam’s 1992 Nature paper establishing AEA as the first identified endocannabinoid is one of the landmark papers of modern neuropharmacology, and the on-demand synthesis/degradation model it revealed changed how we think about retrograde synaptic signaling entirely. We have a lot of respect for what this molecule did for the field. That’s not why it’s here.

The scoring problem with AEA is the gap between its biological importance and its utility as an investigator-administered compound. Plasma half-life on the order of minutes, driven by FAAH-mediated degradation, means exogenous AEA doesn’t survive long enough to produce a sustained pharmacological effect in most research preparations. The field solved this problem years ago: if you want to study endocannabinoid tone, you reach for a FAAH inhibitor like URB597 or PF-04457845, not the substrate itself. As a directly administered compound, AEA scores poorly on translational signal because theres essentially nothing to translate. You can’t build a dosing study around a molecule with a half-life measured in minutes.

What saves it from the bottom of the library is bench utility. If youre running a receptor binding assay, characterizing a novel CB1 ligand, or studying FAAH enzyme kinetics, AEA is the reference standard you need. The secondary TRPV1 and PPAR-gamma activity gives it a multi-target profile that matters when you’re trying to dissect endocannabinoid signaling more broadly. A few serious labs are still working on whether CB1/TRPV1 co-activation accounts for the cleaner preclinical analgesia data coming out of the system, and that work requires AEA specifically rather than a synthetic substitute.

The endocannabinoid system remains genuinely active research territory. CB1/CB2 modulation, FAAH and MAGL inhibition strategies, and AEA’s involvement in neuroinflammation and stress signaling are live areas with real funding and real open questions. AEA sits at the center of that biology, but the research action has shifted to the pharmacological tools that modulate the system rather than to the endogenous ligand itself. We think about it the way we’d think about a high-value reference standard: indispensable for certain assays, not a compound you’d build a 2025 research program around.

Differentiation scores relatively well because AEA is the canonical endogenous CB1 agonist and cant be substituted in studies where endogenous-agonist pharmacology is the specific question. But low translational signal and modest novelty pull the overall to where it lands. Serious endocannabinoid investigators need AEA in the freezer. They’re not writing grants around it.

Novelty

35

Mechanism promise

48

In-category differentiation

58

Evidence quality

50

Translational signal

22

Research bench value

70

Rationale AEA earns solid bench-value marks as the canonical CB1 reference standard and FAAH substrate, but near-zero translational signal from FAAH-mediated rapid degradation and 33 years of mature literature pull the overall well below mid-range. The research action has migrated to FAAH inhibitors; AEA itself is the tool you measure against, not the compound you investigate.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endocannabinoid (N-arachidonoylethanolamine)

The principal endogenous CB1 receptor agonist; a fatty acid amide neurotransmitter implicated in mood, pain, and reward.

Abstract

Anandamide (N-arachidonoylethanolamine, AEA; CAS 94421-68-8; molecular formula C22H37NO2; molecular weight 347.53) is the principal endogenous CB1 receptor agonist, isolated by Devane and Mechoulam in 1992 (Nature). The name derives from the Sanskrit ananda (bliss). The compound is synthesized on-demand from membrane phospholipid precursors via NAPE-PLD and degraded primarily by fatty acid amide hydrolase (FAAH); the on-demand synthesis-degradation kinetics produce highly localized signaling without the persistent receptor occupation typical of conventional neurotransmitters. CB1 affinity is approximately 89 nM with full agonist activity; secondary TRPV1 and PPAR-gamma activity. Plasma half-life is on the order of minutes, extremely short owing to rapid FAAH-mediated degradation. Used as the canonical endocannabinoid in academic neuroscience and as a substrate in FAAH inhibitor research. The administration of exogenous anandamide as a drug is impractical owing to the short half-life; FAAH inhibitors (URB597, PF-04457845) are used to elevate endogenous anandamide instead.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-323Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
N,N-Dimethyltryptamine (N,N-DMT)

Endogenous tryptamine / 5-HT2A agonist

An endogenous tryptamine; the principal psychoactive constituent of ayahuasca; a high-affinity 5-HT2A receptor agonist.

Abstract

N,N-Dimethyltryptamine (N,N-DMT; CAS 61-50-7; molecular formula C12H16N2; molecular weight 188.27) is an endogenous and exogenous tryptamine alkaloid identified in many plants (notably Mimosa hostilis and Psychotria viridis) and at trace concentrations in mammalian tissue. The compound is the principal psychoactive constituent of ayahuasca brews, where harmala beta-carbolines provide MAO-A inhibition that allows oral DMT activity. Pharmacologically, DMT is a high-affinity full agonist at 5-HT2A (Ki approximately 75 nM), 5-HT1A, and 5-HT2C receptors with secondary activity at sigma-1, TAAR1, and other targets. Plasma half-life is extremely short (approximately 15 minutes) owing to rapid MAO-A degradation; oral administration without MAO inhibition is essentially inactive. Behavioral effects include intense visual imagery, altered sense of time, and (at higher doses) sense of communicating with autonomous entities. Approximately 30 active research and clinical trials of DMT and analogs are underway as of 2024 for depression and other psychiatric indications. Schedule I in the US under the CSA. Used as the canonical classical psychedelic in academic neuroscience.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-340Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Loratadine

Plain-language summaryIntrigue 44 / 100

Loratadine, sold as Claritin, is a second-generation antihistamine that is technically a prodrug: most of its clinical effect comes from the active metabolite desloratadine generated by the liver. Like cetirizine it stays largely peripheral, producing allergy relief without significant sedation or anticholinergic effects. It has somewhat lower H1 affinity than cetirizine but a longer duration of action, supporting once-daily dosing. The choice between loratadine, cetirizine, and fexofenadine is largely a matter of individual tolerability and onset preference. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

32/100

Canonical reference antihistamine superseded by its own metabolite; minimal research frontier value

Look, loratadine is Claritin. It’s been on pharmacy shelves since 1993, it’s been OTC since 2002, and if your grandmother has seasonal allergies she probably has a box in her medicine cabinet. That’s not a knock on the compound exactly, but it tells you everything you need to know about its position in a research library built around frontier science.

The mechanism is single-receptor competitive H1 antagonism in the peripheral compartment. That’s it. There’s no dual-target story, no allosteric angle, no novel signaling cascade. The reason it doesn’t make you sleepy is CNS impermeability, which is a pharmacokinetic feature, not a mechanistic surprise. Schering-Plough figured this out thirty years ago and the field hasn’t needed to revisit it since.

What makes the differentiation score particularly bad is that loratadine is a prodrug of desloratadine, which has roughly 250-fold higher H1 affinity (0.4 nM vs. ~100 nM) and a much longer half-life. Clarinex — desloratadine — exists. If you’re running H1 biology and you need a clean peripheral antihistamine probe, theres almost no reason to reach for loratadine over its own active metabolite. Add fexofenadine (P-gp substrate, even cleaner CNS exclusion) and cetirizine (higher affinity, different selectivity profile) and loratadine occupies a pretty awkward middle ground.

Where loratadine earns real credit is in bench value as a reference standard. The abstract correctly identifies it as the canonical non-sedating H1 antihistamine in research. If you’re characterizing a novel compound’s CNS penetration profile, or running histamine challenge experiments with a well-defined comparator, loratadine is a legitimate tool. The evidence quality and translational scores also reflect decades of well-designed trials, regulatory review across multiple jurisdictions, and extensive post-marketing data. That’s real. It’s just not interesting from a discovery standpoint.

We don’t see a novel indication story here that would change the calculus. There’s some scattered literature on mast cell involvement and inflammatory pathways beyond pure H1 blocking, but nothing with the kind of signal that would reframe this as an active frontier target. The CYP3A4/2D6 metabolism and its drug interaction profile are worth noting for stack work, not for discovery research.

Honestly, if loratadine is in your library, it’s there as a control compound and a sourcing sanity check, not because bench scientists are racing to study it. Score reflects that reality.

Novelty

12

Mechanism promise

15

In-category differentiation

12

Evidence quality

75

Translational signal

65

Research bench value

35

Rationale Loratadine’s high evidence and translational scores reflect three decades of solid clinical data, but those scores are offset heavily by near-floor novelty, mechanism, and differentiation: it is a 1993-approved OTC prodrug whose active species (desloratadine) is separately marketed and pharmacologically superior. The calculated overall of 32 lands without a hard cap binding; the score reflects a compound that functions primarily as a negative-control or reference standard rather than a genuine research target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Second-generation H1 antihistamine (peripheral)

A piperidine second-generation H1 antihistamine; a non-sedating allergy medication and the prodrug of desloratadine.

Abstract

Loratadine (ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate; CAS 79794-75-5; molecular formula C22H23ClN2O2; molecular weight 382.88) is a piperidine second-generation H1 antihistamine developed at Schering-Plough and approved by the FDA in 1993 (Claritin). H1 affinity is approximately 100 nM, lower than cetirizine but with similar peripheral selectivity (minimal CNS penetration). The principal active species is the metabolite desloratadine (formed via CYP3A4 and CYP2D6), which has higher H1 affinity (approximately 0.4 nM) and longer half-life; desloratadine is marketed separately as Clarinex. Plasma half-life of loratadine is approximately 8 hours; desloratadine half-life is approximately 27 hours. Approved indications: allergic rhinitis, urticaria. Sedation incidence is approximately 8 percent (similar to placebo in most trials), the lowest of the second-generation antihistamines. Used as the canonical non-sedating H1 antihistamine in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-357Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Edaravone

Plain-language summaryIntrigue 70 / 100

Edaravone is a small molecule that mops up free radicals (reactive oxygen species that damage neurons during stress). Mitsubishi-Tokyo developed it in Japan, where it was approved in 2001 for acute ischemic stroke. The FDA later approved it in 2017 for ALS based on a Japanese phase 3 trial showing slowed functional decline in early-stage patients with preserved breathing capacity. The benefit is real but modest, and only a subset of ALS patients qualify. An oral version arrived in 2022, replacing the original IV-only protocol. Edaravone is the canonical free-radical scavenger drug in neurology research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

FDA-approved ROS scavenger for ALS and stroke, useful reference compound but not frontier research

Look, edaravone has a genuinely interesting story on paper: a pyrazolone compound that scavenges peroxyl and hydroxyl radicals, approved in Japan for acute ischemic stroke back in 2001 and then FDA-approved for ALS in 2017 under Radicava. Thats a real clinical track record. The oral formulation (Radicava ORS) added in 2022 improved the accessibility picture considerably. So why aren’t we more excited about it?

The mechanism is the issue. Free radical scavenging as a primary MoA is one of those ideas that looks elegant until you zoom out and count how many antioxidant compounds have failed to translate in neurodegeneration trials. Oxidative stress is absolutely real in ALS pathology, and edaravone’s Japanese phase 3 (MCI186-19) did show slowed functional decline on the ALSFRS-R. But that trial enrolled a carefully selected subset: early disease, preserved respiratory function, no comorbidities that would confound. Whether the signal holds in broader populations is genuinely contested. The Japanese and US regulatory bodies accepted it; a meaningful portion of neurologists remain unconvinced of real efficacy in typical ALS patients.

As a research tool, edaravone’s strongest role is probably as the canonical ROS scavenger reference compound in neurology and ischemic injury models. If you’re running oxidative stress assays in neural cell lines or rodent stroke preparations, it’s a clean, well-characterized probe with predictable pharmacokinetics (plasma half-life around 4.5 hours). That utility is real. It’s not going to answer questions that N-acetylcysteine or MnTBAP couldn’t also probe, but the regulatory-grade characterization makes it a credible positive control in publication-facing work.

What we like: the ALS approval gives investigators a legitimate clinical hook, and edaravone is one of only two approved pharmacological options for the disease (alongside riluzole), which means it gets used in the field whether researchers are excited by the mechanism or not. The transition to oral dosing also solves some practical barriers for repeat-exposure study designs.

What we don’t like: free radical scavenging is not a frontier mechanism. That’s been the central critique of the entire antioxidant therapeutic category for decades. The subset-specificity of the phase 3 data makes translational extrapolation genuinely uncertain, and the compound itself doesn’t open any research question that other tools can’t address. Honestly, edaravone sits in the ‘approved tool with modest novelty’ bucket. Researchers in ALS biology will have it in their toolkit by necessity; investigators outside that specific indication don’t have strong reason to prioritize it over more targeted probes.

Novelty

30

Mechanism promise

28

In-category differentiation

42

Evidence quality

60

Translational signal

60

Research bench value

55

Rationale Edaravone earns its novelty and mechanism scores from a mature, crowded antioxidant class with a poor track record in broader neurodegeneration; the ALS approval via MCI186-19 is real but the carefully selected subset blunts translational confidence. Evidence and translational scores are lifted by FDA approval, but the compound firmly occupies ‘approved workhorse’ territory rather than anything a frontier investigator would reprioritize around.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Free radical scavenger

A pyrazolone free radical scavenger; approved in Japan and the US for amyotrophic lateral sclerosis (ALS) and acute ischemic stroke.

Abstract

Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one; CAS 89-25-8; molecular formula C10H10N2O; molecular weight 174.20) is a pyrazolone free radical scavenger developed at Mitsubishi-Tokyo Pharmaceuticals. Originally approved in Japan in 2001 for acute ischemic stroke (Radicut), and in 2017 approved by the FDA for amyotrophic lateral sclerosis (Radicava). Mechanism: edaravone scavenges peroxyl, hydroxyl, and other reactive oxygen species, reducing oxidative damage to neurons and the surrounding glia in the affected region. The ALS approval was supported by a Japanese phase 3 trial (MCI186-19) demonstrating slowed functional decline (ALSFRS-R score) in a subset of patients with early disease and preserved respiratory function. Initially IV-only; an oral formulation (Radicava ORS) was approved in 2022. Plasma half-life is approximately 4.5 hours. Used as the canonical free radical scavenger in neurology research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-372Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Progesterone (Research)

Plain-language summaryIntrigue 65 / 100

Progesterone is the principal endogenous progestogen, built from cholesterol via pregnenolone in the corpus luteum, adrenal cortex, and (in pregnancy) placenta. It activates the progesterone receptor with high affinity and also has interesting side effects: it antagonizes mineralocorticoid receptors (driving sodium loss) and its metabolite allopregnanolone is a powerful positive modulator of GABA-A receptors (driving sedation). Approved for menopausal hormone therapy paired with estrogen for endometrial protection, IVF luteal support, secondary amenorrhea, and preterm birth prevention. Oral micronized progesterone hits the liver hard and produces sedating allopregnanolone, while vaginal and transdermal forms give cleaner PR effects. Plasma half-life of the parent is short (5 to 20 minutes). Canonical PR agonist. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

48/100

Canonical endogenous PR agonist; mature approved-drug evidence base, low novelty, infrastructure-grade bench tool

Look, progesterone is the compound you already have on the bench before you start designing experiments. It’s the canonical endogenous progestogen, the reference PR agonist against which everything else in its class gets compared. That’s a real and meaningful role. It’s just not what makes something an exciting research target in 2026.

The mechanism is worth unpacking because its actually more layered than the single-receptor framing suggests. High-affinity PR agonism drives the reproductive and endometrial effects everyone knows. Weak glucocorticoid receptor activity produces a mineralocorticoid-antagonist fingerprint that contributes to natriuretic effects. And first-pass hepatic conversion to allopregnanolone produces GABA-A positive allosteric modulation — which is why oral micronized progesterone (Prometrium) reliably produces sedation in a way vaginal forms don’t. That last piece is where the most interesting current biology lives. Brexanolone, which is essentially IV allopregnanolone, got FDA approval for postpartum depression in 2019, and the neurosteroid GABA-A PAM space is genuinely active right now. But the excitement is about synthetic neurosteroid analogs — zuranolone, ganaxolone, next-generation GABA-A selective compounds. Progesterone the compound is upstream infrastructure for that story, not the lead character.

The evidence base is as mature as it gets for a non-blockbuster pharmaceutical. Multiple phase 3 RCTs, approved across HRT, assisted reproductive technology, secondary amenorrhea, and intramuscular preterm birth prevention. The translational arrow is solid for those established uses. Where it gets instructive: the TBI neuroprotection story once looked promising. ProTECT II phase 2 showed signal, the mechanistic rationale was plausible, and then the ProTECT III trial was definitively negative. That failure matters — it’s a clean example of how compelling preclinical work and early phase 2 signal can collapse under a well-powered phase 3, and it appropriately cooled enthusiasm for progesterone as a neuroprotective research target.

For bench use, progesterone is straightforward infrastructure. It’s the reference standard for PR biology, reproductive physiology studies, and neurosteroid pathway work. Sourcing is genuinely easy — multiple suppliers with USP/EP-grade material, well-characterized reference standards widely available. Reconstitution for in vitro work is routine in ethanol or DMSO. Nothing technically demanding here.

What we dont love: novelty is essentially nil for the compound itself in 2026. The frontier science is at the level of synthetic neurosteroid analogs and selective PR modulators, not progesterone as a primary investigational compound. If you’re building a research program, progesterone is part of your toolkit, not your lead. It earns its place as a reference standard and a component of neurosteroid pathway studies, but it’s not where you’d place your exploratory bets. Score accordingly.

Novelty

20

Mechanism promise

40

In-category differentiation

45

Evidence quality

72

Translational signal

68

Research bench value

60

Rationale Progesterone is the reference-standard PR agonist with a thoroughly characterized multi-receptor pharmacology (PR, weak GR, GABA-A via allopregnanolone metabolite) and an approved-drug evidence base spanning HRT, ART, and preterm birth prevention. The interesting neurosteroid science has largely migrated to synthetic analogs like zuranolone and ganaxolone; progesterone itself scores low on novelty and differentiation, pulling the overall to 48 despite solid evidence and translational signal.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous progestogen / PR agonist

The principal endogenous progestogen; a progesterone receptor agonist with luteal phase, gestational, and neurosteroid functions.

Abstract

Progesterone (pregn-4-ene-3,20-dione; CAS 57-83-0; molecular formula C21H30O2; molecular weight 314.46) is the principal endogenous progestogen, biosynthesized from cholesterol via pregnenolone in the corpus luteum, adrenal cortex, and (during pregnancy) placenta. The compound is a high-affinity progesterone receptor (PR) agonist with secondary effects at the glucocorticoid receptor (mineralocorticoid antagonism contributing to natriuretic effects) and at GABA-A receptors (the pregnanolone metabolite is a positive allosteric modulator producing sedation). Approved indications: menopausal hormone therapy (combined with estrogen for endometrial protection in women with intact uterus), assisted reproductive technology luteal support, secondary amenorrhea, and prevention of preterm birth (intramuscular formulation). Oral micronized progesterone (Prometrium) is highly subject to first-pass metabolism producing the sedating allopregnanolone metabolite; vaginal and transdermal forms produce more direct PR effects with less sedation. Plasma half-life is short (5 to 20 minutes for parent; metabolites variable). Used as the canonical PR agonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-388Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Donepezil

Plain-language summaryIntrigue 75 / 100

Donepezil, sold as Aricept, is the most prescribed acetylcholinesterase inhibitor for Alzheimer disease. It selectively raises brain acetylcholine to compensate for cholinergic neuron loss in dementia. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

Mature gold-standard AChE inhibitor with unmatched clinical data but negligible research novelty

Look, donepezil is the reference standard for its entire drug class and thats not nothing. Thirty years of clinical data, FDA approval across three dementia subtypes, better pharmacokinetics than anything else in the AChE inhibitor family. If you’re building a research program around cholinergic pharmacology, donepezil is the tool you reach for to establish a benchmark. That’s genuine bench value and we’re crediting it.

Here’s the thing though: the mechanism is a single, thoroughly characterized enzyme inhibition. Acetylcholinesterase is not a frontier target. The cholinergic hypothesis of Alzheimer disease has been researched continuously since the early 1980s, and donepezil is its most refined expression. The greater-than-1000-fold selectivity over butyrylcholinesterase is impressive engineering, but it doesn’t add new pharmacology. You get more ACh at the synapse. That’s it. The compound has essentially no significant secondary receptor activities at therapeutic concentrations, and the clean profile that makes it clinically useful is the same thing that makes it mechanistically uninteresting.

The clinical picture reinforces the research picture. Multiple Phase 3 RCTs confirm real, consistent effects on ADAS-cog and MMSE in Alzheimer populations. The effects are small, symptomatic, and non-disease-modifying. The field’s attention has largely moved toward amyloid-directed biologics, tau pathology, and neuroinflammation. Donepezil sits on the approved-drug shelf while the genuinely interesting work happens elsewhere.

There are niche angles that keep donepezil relevant as a tool: some groups are probing sigma-1 receptor co-pharmacology, and the cognitive-enhancement literature in healthy subjects occasionally runs donepezil as a comparator or probe. Recent interest in Lewy body dementia and sleep architecture represents maybe the most active current fringe. None of those are sufficient to move the novelty needle in a meaningful way.

What we like: the pharmacokinetics are genuinely excellent for a research setting. Once-daily oral dosing, essentially complete bioavailability, clean hepatic metabolism via CYP2D6 and CYP3A4. If you need a cholinergic reference compound, donepezil is the professional choice. What we don’t like for a research library context: you’re not going to answer a new question with it. The mechanism is characterized, the population response is characterized, and the ceiling on what AChE inhibition can do in humans has been fairly well defined by decades of modest-but-real phase 3 results.

Overall, donepezil earns its place as a serious reference tool, and the evidence base is one of the strongest in this library. But it’s not a frontier compound. This is mature, proven cholinergic pharmacology, and the score reflects that honestly.

Novelty

20

Mechanism promise

28

In-category differentiation

50

Evidence quality

82

Translational signal

68

Research bench value

50

Rationale Donepezil leads its class on selectivity and evidence depth, but the mechanism is a single well-characterized enzyme inhibition exhaustively studied for three decades; high evidence and translational scores are offset by minimal novelty and mechanism promise, placing this squarely in the mature-but-uninspiring tier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective acetylcholinesterase inhibitor

A piperidine-class selective reversible acetylcholinesterase inhibitor, FDA-approved as Aricept for Alzheimer disease, with the largest clinical evidence base of the AChE inhibitor class.

Abstract

Donepezil (Aricept; (R/S)-2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one hydrochloride; CAS 120014-06-4; molecular formula C24H29NO3; molecular weight 379.49) is a piperidine-class selective reversible acetylcholinesterase inhibitor developed by Eisai and approved by the FDA in 1996 for mild, moderate, and severe Alzheimer disease. The compound has the highest AChE selectivity (over 1000-fold versus butyrylcholinesterase) of the marketed AChE inhibitors and a long plasma half-life (70 hours) that supports once-daily dosing. Mechanism is selective AChE inhibition without significant secondary activities at nicotinic receptors or other targets. The clinical evidence base in Alzheimer disease is extensive; multiple Phase 3 trials demonstrate small but consistent improvements in cognitive endpoint measures (ADAS-cog, MMSE) and global functional status. The compound is also approved for vascular dementia and Parkinson disease dementia in some jurisdictions. Pharmacokinetics: oral bioavailability essentially complete; metabolism is hepatic via CYP2D6 and CYP3A4 with minor active metabolites. Approved doses are 5 to 23 mg per day; the 23 mg formulation was approved in 2010 for severe Alzheimer disease. Schedule status: prescription-only but not federally scheduled.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-046Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 61 62 63 64 65 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.